Bristol-Myers Squibb Company (BMY)

NYSE: BMY · IEX Real-Time Price · USD
78.29
-0.42 (-0.53%)
Jun 29, 2022 12:47 PM EDT - Market open
-0.53%
Market Cap 166.67B
Revenue (ttm) 46.96B
Net Income (ttm) 6.25B
Shares Out 2.13B
EPS (ttm) 2.82
PE Ratio 27.73
Forward PE 9.94
Dividend $2.11 (2.70%)
Ex-Dividend Date Jun 30, 2022
Volume 4,077,041
Open 78.70
Previous Close 78.70
Day's Range 77.99 - 79.17
52-Week Range 53.22 - 80.59
Beta 0.48
Analysts Buy
Price Target 82.23 (+5.0%)
Earnings Date Jul 27, 2022

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients w... [Read more...]

Industry Pharmaceuticals
Founded 1887
CEO Giovanni Caforio
Employees 32,200
Stock Exchange NYSE
Ticker Symbol BMY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 28 analysts, the average rating for BMY stock is "Buy." The 12-month stock price forecast is 82.23, which is an increase of 5.04% from the latest price.

Price Target
$82.23
(5.04% upside)
Analyst Consensus: Buy
Stock Forecasts

News

5 S&P 500 Stocks Ready to Break Out

Although Wall Street is hurting right now, not all S&P 500 stocks are getting thrashed. And these beauties are getting ready to break out.

Other symbols: DPZIBMLLYLYT

Here's one sector that offers ‘offense, defense, growth and value'

Healthcare is the one sector that has everything an investor needs to navigate the market uncertainty, says Virtus Investment Partners' Joe Terranova. “XLV” is down nearly 10% year-to-date.

Investors Need Not Be Alarmed by Drug Patent Expirations

Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax.

All-time highs for pharma stocks: Names to trade now

Big pharma surges, and here are the names to trade. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Dan Nathan, Courtney Garcia and Karen Finerman.

Other symbols: LLYMRKXLV

Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion

Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.

The 2 Best Sectors to Invest in Right Now

All of the top 10 stocks that have gained 20% or more this year are in these two sectors.

Other symbols: CVXVRTXXOM

Final Trades: CHPT, BMY, WMT & XBI

The final trades of the week. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Steve Grasso, Guy Adami and Pete Najarian.

Other symbols: CHPTWMTXBI

U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphom...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--U.S. FDA Approves BMS's CAR T Cell Therapy Breyanzi for Use After One Prior Therapy for Relapsed or Refractory Large B-cell Lymphoma

Bristol Myers must face $6.4 billion lawsuit over delayed cancer drug

A U.S. judge on Friday refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co of delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which...

Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preservi...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE:BMY) today announced new post-hoc analyses from the Zeposia (ozanimod) Phase 3 DAYBREAK open-label extension (OLE) and Phase 3 ...

New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Tre...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE:BMY) today announced new data on COVID-19 vaccine responses in participants treated with Zeposia (ozanimod) from the ongoing Ph...

3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist

These stocks offer dividend yields ranging from 2% to an astronomical 7.1%.

Other symbols: BTIFDX

Bristol Myers' (BMY) Breyanzi sBLA Receives EMA Validation

The EMA validates Bristol Myers' (BMY) type II variation application for the label expansion of Breyanzi for treating relapsed/refractory large B-cell lymphoma after first-line therapy.

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Bcell--European Medicines Agency Validates BMS's Application for CAR T Cell Therapy Breyanzi....

5 Stocks Warren Buffett Has Aggressively Sold Since 2022 Began

One of Berkshire Hathaway's longest-held stocks was given the heave-ho in the first quarter.

Other symbols: ABBVRPRXVZWFC

2 Cheap Stocks to Buy Right Now

These stocks are outperforming the market this year.

Other symbols: JAZZ

Bristol Myers Squibb Announces Dividend

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-four cents ($0.54) per share on the $.10 ...

Bristol Myers Squibb Elects Deepak L. Bhatt, M.D.

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Deepak L. Bhatt, M.D., MPH., to the Board, effective June 14, 2022. Dr. ...

Bristol Myers (BMY) Up 20.4% YTD: Will the Momentum Continue?

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.

7 Blue-Chip Stocks With Strong Dividend Yields

Blue-Chip stocks are particularly attractive in volatile times like now. These picks include a strong dividend as well.

Other symbols: AVGOBPCATMCDMOPG

Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2022 on Wednesday, July 27, 2022. Company executives will review financial result...

Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Goldman Sachs' 43rd Annual Global Healthcare Conference in...

Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA

Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.

Dr. Scott Gottlieb on promising new cancer drug data: 'The future is here'

Dr. Scott Gottlieb, former FDA commissioner and CNBC contributor, joins CNBC's 'Squawk Box' to discuss the top drug trial data coming out of the American Society of Clinical Oncology conference in Chicago.

Other symbols: ABBVLLYMRKPFE

7 Cheap Growth Stocks That Won't Stay That Way for Long

Investors foolishly sent these stocks into cheap territory, ignoring the near-term growth prospects that will reward them soon. The post 7 Cheap Growth Stocks That Won't Stay That Way for Long appeared ...

Other symbols: ACLSANETMAOPERIV